Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 1 · 33.3%Very low 0 · 0%Low 2 · 66.7%Moderate 0 · 0%High 0 · 0%

≥ 1 adverse effects · people with drug‐resistant focal epilepsy

Add‐on stiripentol may leads to higher ≥ 1 adverse effects compared with add‐on placebo (low certainty).

1 finding from 1 review

Stiripentol add‐on therapy for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
RR 2.65 [1.08, 6.47]
1 study · 32 participants
Low

Neurological adverse effects · people with drug‐resistant focal epilepsy

Add‐on stiripentol showed no clear difference in neurological adverse effects compared with add‐on placebo (low certainty).

1 finding from 1 review

Stiripentol add‐on therapy for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
RR 2.65 [0.88, 8.01]
1 study · 32 participants
Low

Gastrointestinal adverse events · people with drug‐resistant focal epilepsy

1 finding from 1 review

Stiripentol add‐on therapy for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 32 participants
GRADE not reported